JNJ-42041935 is a potent and selective inhibitor of the enzyme phosphodiesterase 10A (PDE10A), highly expressed in the brain and involved in cAMP/cGMP signaling pathways in striatal neurons. It is utilized in medical research for neurological and psychiatric disorders, including schizophrenia, Huntington's disease, Parkinson's disease, and pain management. This compound helps researchers understand PDE10A's role in these conditions, explore therapeutic strategies, and develop novel treatments. Preclinical studies assess its effects on neural circuits, efficacy in alleviating symptoms of psychiatric disorders, and potential as an analgesic for chronic and neuropathic pain with improved safety profiles compared to existing therapies.